Relevant bibliographies by topics / Platinum(IV)

Academic literature on the topic 'Platinum(IV)'

Author: Grafiati
Published: 4 June 2021
Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Platinum(IV).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Platinum(IV)"

1

Young, Jay A. "Platinum(IV) Chloride." Journal of Chemical Education 86, no. 2 (February 2009): 162. http://dx.doi.org/10.1021/ed086p162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Puddephatt, R. "Platinum(IV) hydride chemistry." Coordination Chemistry Reviews 219-221 (October 2001): 157–85. http://dx.doi.org/10.1016/s0010-8545(01)00325-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Galanski, M., and B. K. Keppler. "Synthesis and Characterization of New Ethylenediamine Platinum(IV) Complexes Containing Lipophilic Carboxylate Ligands." Metal-Based Drugs 2, no. 1 (January 1, 1995): 57–63. http://dx.doi.org/10.1155/mbd.1995.57.

Full text
Abstract:
A series of new ethylenediamine (en) platinum(IV) complexes of the type Pt(IV)enX2A2 , with X2 = cyclobutane-1,1-dicarboxylato (CBDCA), dichloro or bis(decanoato) and A = acetato, dodecanoato, tetradecanoato, hexadecanoato, octadecanoato, adamantanecarboxylato (Ad) or 3α, 12α -diformoxy-5β-cholato (DFCA) were synthesized and characterized by elemental analysis, infrared and NMR (H1 and C13) spectroscopic techniques. Previous platinum(IV) compounds were usually restricted to trans-dihydroxo or trans-dichloro platinum(IV) complexes. Recently trans-dicarboxylato platinum(IV) complexes with mainly acetate, trifluoracetate or short-chain carboxylate groups (<11 carbons) in the axial position have been described in the literature[1,2,3]. In this paper we report on the synthesis and characterization of a new class of ethylenediamine platinum(IV) compounds that have high lipophilic long-chain carboxylate ligands either in the axial or equatorial position. The platinum(IV) compounds with the lipophilic trans-carboxylate ligands in the axial position were prepared by acylation of the trans-dihydroxo platinum(IV) species using an acyl halide in the presence of pyridine. In contrast to previous publications[1] the yields were excellent (up to 94%!).
APA, Harvard, Vancouver, ISO, and other styles
4

Boisen, Michelle M., Jamie L. Lesnock, Scott D. Richard, Sushil Beriwal, Joseph L. Kelley, Kristin K. Zorn, and Robert P. Edwards. "Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer." International Journal of Gynecologic Cancer 26, no. 4 (May 2016): 626–31. http://dx.doi.org/10.1097/igc.0000000000000667.

Full text
Abstract:
ObjectiveOnly 3% of patients with epithelial ovarian cancer (EOC) have a longer treatment-free interval (TFI) after second-line intravenous (IV) platinum chemotherapy than with frontline IV therapy. We sought to examine what impact second-line combination IV/intraperitoneal (IV/IP) platinum therapy might have on the ratio of second-line to first-line TFI in patients treated with second-line IP platinum chemotherapy for first recurrence after front-line IV therapy.MethodsA retrospective analysis of women who received combination platinum-based IV/IP chemotherapy for recurrent EOC between January 2005 and March 2011 was conducted. Patients were identified from the tumor registry, and office records from a large gynecologic oncology practice and patient records were reviewed. The first and second TFIs were defined as the time from the end of previous platinum-based therapy to the start of next therapy.ResultsTwenty-five women received IV/IP chemotherapy for their first EOC recurrence after IV chemotherapy. In 10 patients (40%), we observed a longer TFI after IV/IP chemotherapy than after primary IV chemotherapy. For these 10 patients, the median TFI for primary response was 22 months (range, 15–28), whereas median TFI after IV/IP chemotherapy for recurrent disease was 37 months (range, 12–61).ConclusionsFor EOC patients with limited peritoneal recurrence, 40% of patients had a second-line IP-platinum TFI that exceeded their frontline IV-platinum TFI compared to published data. These data support the use of IV/IP chemotherapy as a treatment for recurrence.
APA, Harvard, Vancouver, ISO, and other styles
5

Choi, Sunhee, Livia Vastag, Yuri C. Larrabee, Michelle L. Personick, Kurt B. Schaberg, Benjamin J. Fowler, Roger K. Sandwick, and Gulnar Rawji. "Importance of Platinum(II)-Assisted Platinum(IV) Substitution for the Oxidation of Guanosine Derivatives by Platinum(IV) Complexes." Inorganic Chemistry 47, no. 4 (February 2008): 1352–60. http://dx.doi.org/10.1021/ic701868b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Choi, Sunhee, Livia Vastag, Yuri C. Larrabee, Michelle L. Personick, Kurt B. Schaberg, Benjamin J. Fowler, Roger K. Sandwick, and Gulnar Rawji. "Importance of Platinum(II)-Assisted Platinum(IV) Substitution for the Oxidation of Guanosine Derivatives by Platinum(IV) Complexes." Inorganic Chemistry 47, no. 9 (May 2008): 3920. http://dx.doi.org/10.1021/ic8005713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Aputen, Angelico D., Maria George Elias, Jayne Gilbert, Jennette A. Sakoff, Christopher P. Gordon, Kieran F. Scott, and Janice R. Aldrich-Wright. "Potent Chlorambucil-Platinum(IV) Prodrugs." International Journal of Molecular Sciences 23, no. 18 (September 9, 2022): 10471. http://dx.doi.org/10.3390/ijms231810471.

Full text
Abstract:
The DNA-alkylating derivative chlorambucil was coordinated in the axial position to atypical cytotoxic, heterocyclic, and non-DNA coordinating platinum(IV) complexes of type, [PtIV(HL)(AL)(OH)2](NO3)2 (where HL is 1,10-phenanthroline, 5-methyl-1,10-phenanthroline or 5,6-dimethyl-1,10-phenanthroline, AL is 1S,2S-diaminocyclohexane). The resultant platinum(IV)-chlorambucil prodrugs, PCLB, 5CLB, and 56CLB, were characterized using high-performance liquid chromatography, nuclear magnetic resonance, ultraviolet-visible, circular dichroism spectroscopy, and electrospray ionization mass spectrometry. The prodrugs displayed remarkable antitumor potential across multiple human cancer cell lines compared to chlorambucil, cisplatin, oxaliplatin, and carboplatin, as well as their platinum(II) precursors, PHENSS, 5MESS, and 56MESS. Notably, 56CLB was exceptionally potent in HT29 colon, Du145 prostate, MCF10A breast, MIA pancreas, H460 lung, A2780, and ADDP ovarian cell lines, with GI50 values ranging between 2.7 and 21 nM. Moreover, significant production of reactive oxygen species was detected in HT29 cells after treatment with PCLB, 5CLB, and 56CLB up to 72 h compared to chlorambucil and the platinum(II) and (IV) precursors.
APA, Harvard, Vancouver, ISO, and other styles
8

Bokach, Nadezhda A., Vadim Yu Kukushkin, and Matti Haukka. "trans-Tetrachloridobis(diphenylacetonitrile)platinum(IV)." Acta Crystallographica Section E Structure Reports Online 65, no. 6 (May 14, 2009): m636. http://dx.doi.org/10.1107/s1600536809016535.

Full text
Abstract:
In the title compound, [PtCl4(C14H11N)2], the Pt atom lies on an inversion center and has a distorted octahedral environment. The main geometric parameters are Pt—N = 1.960 (5) Å, and Pt—Cl = 2.3177 (12) and 2.3196 (12) Å. The N[triple-bond]C bond is a typical triple bond [1.137 (7) Å]. The Pt—N[triple-bond]C—C unit is almost linear, with Pt—N—C and N—C—C angles of 174.6 (4) and 177.1 (6)°, respectively.
APA, Harvard, Vancouver, ISO, and other styles
9

Look, Jennifer L., Douglas D. Wick, James M. Mayer, and Karen I. Goldberg. "Autoxidation of Platinum(IV) Hydrocarbyl Hydride Complexes To Form Platinum(IV) Hydrocarbyl Hydroperoxide Complexes." Inorganic Chemistry 48, no. 4 (February 16, 2009): 1356–69. http://dx.doi.org/10.1021/ic801216r.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Reinartz, Stefan, Maurice Brookhart, and Joseph L. Templeton. "Platinum(II) and Platinum(IV) Acyl and Formyl Complexes." Organometallics 21, no. 2 (January 2002): 247–49. http://dx.doi.org/10.1021/om010772j.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Platinum(IV)"

1

Shaili, Evyenia. "Photoactivatable platinum (IV) anticancer complexes." Thesis, University of Warwick, 2013. http://wrap.warwick.ac.uk/59800/.

Full text
Abstract:
In this work, trans-diazido Pt(IV) complexes with general formula [Pt(N3)2(OH)(OCOR)(pyr)2] (where OCOR is a carboxylate axial ligand) and [Pt(N3)2(OH)2(L1)(L2)] (where L1 and L2 are aromatic N-heterocyclic ligands) have been synthesised and characterised. The chemical and photochemical properties of these complexes, as well as their photobiological behaviour, have been studied in order to check their potential as photoactivatable anticancer drugs. Four trans-diazido Pt(IV) complexes with general formula trans, trans, trans- [Pt(N3)2(OH)(OCOR)(pyr)2] (OCOR= succinate, 4-oxo-4-propoxybutanoate, Nmethylisatoate and succinate-(RGD)f peptide ligands) have been obtained by axial derivatisation of one hydroxido ligand from trans, trans, trans- [Pt(N3)2(OH)2(pyr)2]. The crystal structures of three axially-derivatised complexes have been determined by X-ray diffraction. Photoirradiation studies have shown an improved photoactivity of the carboxylate versus the dihydroxido complexes at the longer wavelengths. Release of the axial ligands was observed in the studied complexes. This fact is especially relevant in the case of the Pt(IV)-(cRGD)f complex, where the RGD was incorporated as a tumour cell targeting moiety. DFT-TDDFT calculations performed on the complex trans, trans, trans- [Pt(N3)2(OH)(Succ)(pyr)2] showed dissociative transitions at longer wavelength, which could explain the photolability observed in these carboxylate derivatives. Studies of photoactivation of the diazido Pt(IV) complexes in the presence of 5’- GMP indicate the formation of a mono-GMP Pt(II) adduct as main photoproduct, therefore DNA could be considered a potential target site for these anticancer compounds. Additionally, EPR studies showed that azidyl radical release was observed when complexes bearing the succinate and 4-oxo-4-propoxybutanoate ligands were irradiated with green light. No such result was obtained for the dihydroxo precursor showing that these complexes could be phototoxic with longer wavelength light activation. Seven trans-diazido Pt(IV) complexes, trans, trans, trans- [Pt(N3)2(OH)2(L1)(L2)] (where L1 and L2 are pyridine, 2-picoline, 3-picoline, 4- picoline, thiazole or 1-methylimidazole ligands), have been obtained by oxidation of the corresponding trans-[Pt(N3)2(L1)(L2)] precursor. The X-ray crystal structures have been determined for four Pt(IV) diazido complexes from this family of compounds. Photoirradiation studies indicate that the incorporation of a sterically demanding ligand, e.g. trans, trans, trans-[Pt(N3)2(OH)2(2-pic)(pyr)], greatly enhances the photoactivity in these complexes. DFT-TDDFT calculations are in agreement with these results, since higher intensity transitions were observed for such complex at longer wavelength. Phototoxicity studies carried out on A2780, A2780cis and OE19 cell lines with the trans, trans, trans-[Pt(N3)2(OH)2(pyridine)(n-picoline)] family concluded that steric hindrance close to the platinum centre does not favour phototoxicity. Most of the complexes were equally potent in cisplatin resistance against the ovarian cancer cell line (A2780cis), except [Pt(N3)2(OH)2(3-pic)2] and [Pt(N3)2(OH)2(4-pic)2] which exhibited some cross resistance. All of the complexes tested in both OE19 and A2780 cell lines have shown less sensitivity to OE19 than to A2780. Studies in S. pombe yeast strains (WT and ΔRad3) with trans, trans, trans-[Pt(N3)2(OH)2(pyr)2] suggest that DNA is potentially an important target for this type of compounds, although other targets are not excluded. Furthermore, live-cell confocal microscopy was performed on A2780 cells treated with the complex trans, trans, trans-[Pt(N3)2(OH)2(pyr)2] and irradiated with a low dose of blue light. The cell death, monitored by propidium iodide uptake, was captured occurring 2 h 30 min post activation.
APA, Harvard, Vancouver, ISO, and other styles
2

Butler, Jennifer Suzanne. "Photodecomposition pathways for photoactivatable platinum(IV) diazido anticancer complexes." Thesis, University of Warwick, 2014. http://wrap.warwick.ac.uk/65794/.

Full text
Abstract:
Photo-activatable platinum(IV) diazido complexes with the general formula of trans,trans,trans-[Pt(N3)2(OH)(X)(py)(am1)] (X is a hydroxide or carboxylate and am1 is an aliphatic/aromatic amine) show dark-stability under physiological conditions but can induce a photo-cytotoxic effect in cancer cells after irradiation with UVA, blue and/or green light. These platinum(IV) diazido complexes can platinate DNA and induce different lesions that are distinctly different from those generated by the anticancer drug cis-platin. Through the use of EPR, multinuclear NMR, and UV-visible absorption spectroscopy, as well as mass spectrometry and some cell studies, this thesis aims to investigate the pathways of photochemical decomposition and in particular the release of azidyl ligands and their subsequent involvement in photo-cytotoxicity. Firstly, the irradiation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (40, py = pyridine) with blue light in the presence of the spin trap 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) led to the detection of a characteristic quartet-of-triplets EPR spectrum, assigned to the azidyl radical adduct, DMPO-14N3. Irradiation of 15N-40, led to the detection of a quartet-of-doublets EPR spectrum as assigned to the DMPO-15N3 spin adduct. This confirmed that the ●N3 radicals arose from the platinum(IV)- bound azide. The DMPO-N3 spin adduct was also detected from the photoirradiation of trans,trans,trans-[Pt(N3)2(OH)2(MA)(py)] (44, MA = methylamine) with blue light. A greater yield in the DMPO-N3 spin adduct was formed in PBS/D2O. This effect was attributed to the Brownian motion of the ●N3 radicals. Interestingly, photoirradiation in the cell culture medium-, RPMI-1640 led to a reduction in the DMPO-N3 spin adduct. This reduction was accredited to the variety of components present in the cell culture medium which could behave as radical quenchers. Alternative nitrone spin traps, -4-pyridyl-1-oxide-N-tert-butylnitrone (4-POBN) and 5-diethoxyphosphoryl-5-methyl-1-pyrroline-N-oxide (DEPMPO) also led to the trapping of the azidyl radicals from irradiated 40, forming the 4-POBN-N3 (triplet-of-quartets) and DEPMPO-N3 (octet-of-triplets) spin adducts EPR spectra, respectively. DEPMPO was the most efficient azidyl radical trap; with the DEPMPO-N3 spin adduct possessing the longest lifetime in aqueous media. Extending the wavelength of activation to green light (517 nm), also led to the detection of DMPO-N3 from the photo-irradiation of 40 in RPMI-1640, trans,trans,trans-[Pt(N3)2(OH)(SAD)(py)2] (56,SAD=succinate), trans,trans,trans-[Pt(N3)2(OH)(ethyl-methyl-SAD)(py)2] (57) and trans,trans,trans-[Pt(N3)2(OH)(N-MI)(py)2] (58, N-MI = N-methylisatoate) in H2O/DMF. The DEPMPO-N3 was also detected from the gamma-ray irradiation of 40, which appears to be the first report of the activation of a platinum(IV) diazido anticancer complex with gamma-rays, a procedure which might be useful of clinical use. The azidyl radicals generated from irradiated 40 were unreactive towards both glycine and L-tyrosine. However, in the presence of L-tryptophan the azidyl radicals were quenched. Detection of free azide by 14N NMR spectroscopy confirmed that this quenching mechanism proceeded through a one-electron transfer pathway. The photo-cytotoxicity of 40 was supressed in the presence of low doses of L-tryptophan in A2780 ovarian cancer cells. From this study, it was deduced that the photo-cytotoxicity of 40 is comprised of both an acute (radical) and chronic (DNA platination) based mechanisms. Additionally, certain cancers have reported on the depleted serum levels of L-tryptophan, in particular ovarian cancer cells. This suggests the extent of the photo-cytotoxicity of 40 can be controlled in the presence of L-tryptophan. Photo-irradiation of 40 in the presence of melatonin, an analogue of L-tryptophan was also performed. Despite, the structural similarity between L-tryptophan and melatonin, the presence of the 5-methoxy substituent present in melatonin induced an alternative photo-decomposition pathway of 40. Photo-irradiation of 40 in the presence of melatonin with blue light also led to the detection of the quartet EPR spectrum assigned to the hydroxyl radical adduct, DMPO-OH. Through multinuclear NMR and mass spectrometry the quenching of both the azidyl and hydroxyl radicals by melatonin was determined. Additionally, mass spectrometry also detected a mass adduct attributed to a platinum(II)-melatonin complex. This dual antioxidant and metal-binding ability of melatonin was attributed to the observed photo-protective effect in A2780 ovarian cancer cells. Melatonin regulates circadian rhythms with a maximum concentration during dark hours. Consequently, treatment of antineoplastic tissue with 40 during the hours of melatonin production may be ineffective. Platinum accumulation and absorption has been suggested to be mediated by organic cation transporters (OCTs), in particular OCT2. Irradiation of 40 was monitored in the presence of cimetidine, an OCT2 inhibitor. A new strong absorption band at ca. 354 nm was assigned to an SPtII LMCT band. High resolution mass spectroscopy identified a mass adduct assigned to a novel platinum(II)-cimetidine species. The loss of coordinated pyridine from irradiated 40 as detected by 1H NMR spectroscopy and the quenching of the azidyl radical by cimetidine were correlated with the observed photo-protective effect in HaCaT keratinocytes cells.
APA, Harvard, Vancouver, ISO, and other styles
3

Luedtke, Avery T. "Synthesis, structure, and reactivity of five-coordinate platinum(IV) complexes /." Thesis, Connect to this title online; UW restricted, 2007. http://hdl.handle.net/1773/11565.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Allenbaugh, Rachel J. Schauer Cynthia Karen. "Supramolecular ordering through axial interactions in mono and mixed valent metellomesogenic systems of platinum(II) and platinum(IV)." Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2006. http://dc.lib.unc.edu/u?/etd,360.

Full text
Abstract:
Thesis (Ph. D.)--University of North Carolina at Chapel Hill, 2006.
Title from electronic title page (viewed Oct. 10, 2007). "... in partial fulfillment of the requirements for the degree of the Doctor of Philosophy in the Department of Chemistry." Discipline: Chemistry; Department/School: Chemistry.
APA, Harvard, Vancouver, ISO, and other styles
5

Alderden, Rebecca. "The Distribution of Platinum Complexes in Biological Systems." Thesis, The University of Sydney, 2006. http://hdl.handle.net/2123/1419.

Full text
Abstract:
The toxicity of platinum anticancer drugs presents a major obstacle in the effective treatment of tumours. Much of the toxicity stems from a lack of specificity of the drugs for the sites at which they are able to exert maximum anticancer activity. An improved understanding of the behaviour of the drugs in the tumour environment may assist in the rational design of future platinum anticancer agents with enhanced specificity and reduced toxicity. In the work presented herein, the specificity of two classes of platinum anticancer agents was assessed (platinum(IV) cisplatin analogues and platinum(II) anthraquinone complexes). The interaction of the platinum(IV) agents with DNA, believed to be their main cellular target, was examined using XANES spectroscopy. This experiment was designed to assess the ability of the drugs to interact with DNA and thus exert their anticancer activity. It was shown that the platinum(IV) complexes were not reduced by DNA during 48 hr incubation. It was not possible to conclusively determine whether the interaction of the complexes with DNA was direct or platinum(II) catalysed, or whether interaction had occurred at all. The distribution of platinum(II) anthraquinone complexes and their corresponding anthraquinone ligands in tumour cells (A2780 ovarian and DLD-1 colon cancer cell lines) was investigated. The cytotoxicity of the compounds in DLD-1 cells was also assessed. It was found that the compounds were efficiently taken up into the cells and entered the lysosomal compartments almost exclusively. This suggested that the cytotoxicity of the drugs was caused by lysosomal disruption, or that the platinum complexes were degraded, leaving a platinum species to enter the cell nuclei and interact with DNA. Alternatively, the complexes may bind to proteins and transport into the nuclei of the cells, though with their fluorescence quenched by the protein. The penetration and distribution of platinum(IV) complexes was assessed in DLD-1 multicellular tumour spheroids (established models of solid tumours) using a number of synchrotron techniques, including micro-tomography, micro-SRIXE, and micro-XANES. The complexes were found to be capable of penetrating throughout the entire volume of the spheroids. Micro-XANES indicated that in central and peripheral spheroidal regions, bound platinum species were present largely as platinum(II).
APA, Harvard, Vancouver, ISO, and other styles
6

Alderden, Rebecca. "The Distribution of Platinum Complexes in Biological Systems." University of Sydney, 2006. http://hdl.handle.net/2123/1419.

Full text
Abstract:
Doctor of Philosophy (PhD)
The toxicity of platinum anticancer drugs presents a major obstacle in the effective treatment of tumours. Much of the toxicity stems from a lack of specificity of the drugs for the sites at which they are able to exert maximum anticancer activity. An improved understanding of the behaviour of the drugs in the tumour environment may assist in the rational design of future platinum anticancer agents with enhanced specificity and reduced toxicity. In the work presented herein, the specificity of two classes of platinum anticancer agents was assessed (platinum(IV) cisplatin analogues and platinum(II) anthraquinone complexes). The interaction of the platinum(IV) agents with DNA, believed to be their main cellular target, was examined using XANES spectroscopy. This experiment was designed to assess the ability of the drugs to interact with DNA and thus exert their anticancer activity. It was shown that the platinum(IV) complexes were not reduced by DNA during 48 hr incubation. It was not possible to conclusively determine whether the interaction of the complexes with DNA was direct or platinum(II) catalysed, or whether interaction had occurred at all. The distribution of platinum(II) anthraquinone complexes and their corresponding anthraquinone ligands in tumour cells (A2780 ovarian and DLD-1 colon cancer cell lines) was investigated. The cytotoxicity of the compounds in DLD-1 cells was also assessed. It was found that the compounds were efficiently taken up into the cells and entered the lysosomal compartments almost exclusively. This suggested that the cytotoxicity of the drugs was caused by lysosomal disruption, or that the platinum complexes were degraded, leaving a platinum species to enter the cell nuclei and interact with DNA. Alternatively, the complexes may bind to proteins and transport into the nuclei of the cells, though with their fluorescence quenched by the protein. The penetration and distribution of platinum(IV) complexes was assessed in DLD-1 multicellular tumour spheroids (established models of solid tumours) using a number of synchrotron techniques, including micro-tomography, micro-SRIXE, and micro-XANES. The complexes were found to be capable of penetrating throughout the entire volume of the spheroids. Micro-XANES indicated that in central and peripheral spheroidal regions, bound platinum species were present largely as platinum(II).
APA, Harvard, Vancouver, ISO, and other styles
7

Williams, Burke Scott. "Studies of the reactivities of organometallic complexes containing platinum(IV)-oxygen bonds /." Thesis, Connect to this title online; UW restricted, 2000. http://hdl.handle.net/1773/8703.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhao, Yao. "Synthesis, characterization, photochemistry and anticancer activity of novel photoactivatable platinum(IV) diazidodihydroxido complexes." Thesis, University of Warwick, 2012. http://wrap.warwick.ac.uk/52700/.

Full text
Abstract:
PtIV-diazidodihydroxido complexes are inert in the dark, but can be selectively activated by irradiation with light and become potently cytotoxic towards cancer cells. By site-specific irradiation to tumour tissue, the side-effects to healthy tissue associated with conventional chemotherapeutics, such as cisplatin, can be circumvented. This thesis aims to develop design photoactivatable platinum(IV) diazidodihydroxido complexes to achieve higher photocytotoxicity, lower crossresistance and longer wavelength of activation. A series of PtIV diazidodihydroxido complexes with trans azido, trans hydryxido groups and mixed trans aliphatic/aromatic amines, was designed, synthesized and characterized. Trans, trans, trans-[Pt(N3)2(OH)2(MA)(Py)] (5) and trans, trans, trans-[Pt(N3)2(OH)2(MA)(Tz)] (8) are potently cytotoxic towards A2780, OE19 and HaCaT cell lines upon irradiation with UVA. Remarkably, they also showed potent cytotoxic effects towards A2780cis (cisplatin-resistant ovarian cancer cell subline). Also, the photocytotoxicity towards the A2780, A2780cis, OE19 and HaCaT cell lines upon irradiation with blue light (λmax = 420 nm) is still potent compared to that upon irradiation with UVA. These complexes are highly inert in the absence of light and have almost no dark toxicity. Upon irradiation with UVA/blue light, the complex 5 was observed to release free azide anions N3−, azidyl radicals N3•, nitrogen gas N2 and form nitrene intermediates. It was of importance to discover that singlet oxygen (1O2) is generated from photoreactions in the absence of an exogenous source of oxygen, whereas hydrogen peroxide (H2O2) and hydroxyl radical intermediates did not appear to be formed. Mono-functional and bi-functional Pt adducts were captured from the photoinduced binding of complexes 5 and 8 to 5'-GMP and a DNA oligonucleotide. It was discovered for the first time that the oxidation of 5'-GMP can occur during the photoreaction of complex 5 upon irradiation with UVA. Singlet oxygen and nitrene intermediate generated from this photoreaction are likely to be the cause of the oxidative damage to guanine. 4-Nitropyridine, 2,2'-bipyridine, and terpyridines were used as ligands in novel photoactivable PtIV (di)azido complexes and two were activated by green light. A new two-photon-activatable PtII complex, cis-[PtCl2(MOPEP)2](42), was also designed, synthesized and characterized. It was observed that this complex was sensitive to one-photon excitation below 500 nm and the ligand MOPEP underwent rapid solvent (acetonitrile) substitution upon irradiation. The same photoreaction was also triggered by two-photon excitation with fs-pulses laser light between 600 – 700 nm.
APA, Harvard, Vancouver, ISO, and other styles
9

Getty, April D. "Syntheses and reactivity studies of hydroxo-palladium(II) and amido-platinum(IV) complexes /." Thesis, Connect to this title online; UW restricted, 2001. http://hdl.handle.net/1773/8653.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Garnica, Meza Jose Manuel. "Catalytic and electrochemical study of the cerium (IV)-mercury (I) reaction at platinum surfaces." Thesis, Imperial College London, 1990. http://hdl.handle.net/10044/1/46312.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Platinum(IV)"

1

Campbell, Colm J. Synthesis and study of platinum(II) and platinum(IV) complexes of EDTA derivatives as potential antitumour agents. Dublin: University College Dublin, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Garcia, Stephanie Jocelyn. New platinum(IV) molecular probes: Synthesis, characterization, and DNA binding studies. 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Blackwood, Regan J. An investigation of the cytotoxicity and mechanisms of cell death induced by novel antitumor platinum and palladium (IV) complexes. 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Platinum(IV)"

1

Ford, P. C. "Of Platinum(IV)." In Inorganic Reactions and Methods, 202–4. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470145302.ch76.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Keller, R. N., Therald Moeller, and J. V. Quagliano. "Platinum(IV) Chloride." In Inorganic Syntheses, 253–55. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470132333.ch81.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Clegg, D. E., J. R. Hall, C. H. Brubaker, G. L. Gilbert, and M. Dyke. "Iodo(trimethyl)platinum(IV)." In Inorganic Syntheses, 71–74. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470132418.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Grice, Kyle A., Margaret L. Scheuermann, and Karen I. Goldberg. "Five-Coordinate Platinum(IV) Complexes." In Higher Oxidation State Organopalladium and Platinum Chemistry, 1–27. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-17429-2_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Giedt, D. C., C. J. Nyman, John Young, and R. Kent Murmann. "Tris(ethylenediamine)platinum(IV) Chloride." In Inorganic Syntheses, 239–41. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470132395.ch63.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wong, Daniel Yuan Qiang. "Probing the Platinum(IV) Prodrug Hypothesis. Are Platinum(IV) Complexes Really Prodrugs of Cisplatin?" In Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches, 55–71. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-8594-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kauffman, George B., James Hwa-San Tsai, Lloyd T. Takahashi, J. W. Hogarth, and F. P. Dwyer. "cis - and trans -Tetrachlorobis(diethylsulfide)platinum(IV)." In Inorganic Syntheses, 245–48. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470132395.ch65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kuksuk, Robert M., Wade A. Freeman, Pierre R. Lebreton, George B. Kauffman, and Matthew L. Adams. "cis -Dichlorobis(1, 2-Ethanediamine)-Platinum(IV) Chloride." In Inorganic Syntheses, 314–17. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470132586.ch62.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kamčeva, Tina, and Marijana Petković. "Platinum (IV) Complexes, Inhibition of Porcine Pancreatic Phospholipase A2." In Encyclopedia of Metalloproteins, 1698–703. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-1533-6_546.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wong, Daniel Yuan Qiang. "Induction of Targeted Necrosis with HER2-Targeted Platinum(IV) Anticancer Prodrugs." In Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches, 73–101. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-8594-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Platinum(IV)"

1

Zaltariov, Mirela-Fernanda, Mihaela Avadanei, and Dragos Peptanariu. "Structural and Cytotoxic Evaluation of Platinum(IV) Complexes with Biological Active Ligands." In 2019 E-Health and Bioengineering Conference (EHB). IEEE, 2019. http://dx.doi.org/10.1109/ehb47216.2019.8970005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Okamoto, Yoshinori, Takao Tobe, Koji Ueda, and Nakao Kojima. "Abstract 4485: Anticancer effect of platinum(IV) complex against cisplatin-resistant human ovarian cancer." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4485.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lebedeva, O. V., Yu N. Pozhidaev, A. A. Konovalenko, and R. T. Usmanov. "Composite Polymer-Silicone Adsorbent for Platinum (IV) Ions: Investigation of Models and Absorption Kinetics." In Proceedings of the International Symposium “Engineering and Earth Sciences: Applied and Fundamental Research” (ISEES 2018). Paris, France: Atlantis Press, 2018. http://dx.doi.org/10.2991/isees-18.2018.77.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Stojković, Danijela Lj, Verica V. Jevtić, Đorđe S. Petrović, Sandra S. Jovičić Milić, Nenad L. Vuković, Milena D. Vukić, and Bojan Stojanović. "SYNTHESIS AND CHARACTERIZATION OF PLATINUM(II/IV) COMPLEXES WITH 2-AMINO-5-METHYL-4-PHENYLTHIAZOLE." In 1st INTERNATIONAL Conference on Chemo and BioInformatics. Institute for Information Technologies, University of Kragujevac, 2021. http://dx.doi.org/10.46793/iccbi21.339s.

Full text
Abstract:
This paper examines the synthesis of two new complexes of platinum(II/IV) ion, general formula [PtL2]Cl2 and [PtL2]Cl4, where L is 2-amino-5-methyl-4-phenylthiazole. The structures of the above mentioned compounds were determined by elemental microanalysis, infrared, 1H and 13C NMR spectroscopy.
APA, Harvard, Vancouver, ISO, and other styles
5

Nakai, Tsuyoshi, Motozumi Ando, Yoshihiko Nishino, Yoshinori Okamoto, Koji Ueda, and Nakao Kojima. "Abstract 3646: DNA oxidation induced by platinum(IV) compound in the presence of endogenous reductants." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3646.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ganchimeg, Yu, G. Burmaa, I. Sukhbaatar, S. Alen, T. Narangarav, and O. Nasantogtokh. "Thermodynamics and kinetics of platinum (IV) sorption on the silicon-organic polymer containing thioacetamide groups." In 2013 8th International Forum on Strategic Technology (IFOST). IEEE, 2013. http://dx.doi.org/10.1109/ifost.2013.6616974.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

He, Guangan, Gregory Thiabaud, Kathyrin A. Shelton, Luke J. Segura, Jonathan L. Sessler, Rick A. Finch, Zahid H. Siddik, and Jonathan F. Arambula. "Abstract 1073: Preclinical tissue biodistribution and plasma pharmacokinetic studies with oxaliTEX, a novel platinum(IV)-based oxaliplatin prodrug." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-1073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Felip, E., G. Castro, A. Greystoke, B. Solomon, DSW Tan, C. Grohe, VQ Passos, et al. "Canopy-1: Phase 3 Study of Canakinumab/Placebo + Pembrolizumab + Platinum-chemotherapy in Untreated Stage III b-IV NSCLC pts." In 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0039-3403093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Radojević, Ivana, Marina Mijajlović, Sava Vasić, Jovana Maksimović, Ljiljana Čomić, Miloš Nikolić, and Gordana Radić. "Antibacterial and Antibiofilm Screening of New Platinum(IV) Complexes with some S-Alkyl Derivatives of Thiosalicylic Acid." In 2nd International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2016. http://dx.doi.org/10.3390/ecmc-2-a027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

He, Guangan, Jian Kuang, Abdul R. Khokhar, and Zahid H. Siddik. "Abstract 3513: The underlying basis for divergent cell cycle kinetics following checkpoint activation by cisplatin and a platinum (IV) analog." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3513.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Platinum(IV)"

1

ding, huan, zhuo chen, yue zhang, yuzhi tian, jingming li, jingxiao deng, zhuo feng, yuxiao zhang, and li shi. Efficacy and safety of Aidi injection combined with pemetrexed and platinum chemotherapy for stage III/IV non-small cell lung cancer A protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0039.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ding, Huan, LI Shi, Zhuo Chen, Yue Zhang, Zhiyu Tian, Mingjing Li, Jiaqi Hu, Yushan Wu, Zhuo Feng, and Xiaoyu Zhang. Effificacy and safety of Aidi injection combined with pemetrexed and platinum chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Platinum(IV)' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography